^
Association details:
Biomarker:HRD
Cancer:Breast Cancer
Drug:IDE161 (PARG inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Excerpt:
...Have documented evidence of genetic alterations conferring homologous recombination deficiency 4....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

6093 / 1 - IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors

Published date:
03/15/2023
Excerpt:
Biochemical and cellular assays demonstrate that IDE161 is a potent inhibitor of PAR chain hydrolysis and has anti-proliferative activity in breast and ovarian HRD cancer cell lines with both inherent and acquired PARPi resistance.